(RTTNews) – Revolution Medicines, Inc. (RVMD), a clinical-stage oncology firm creating focused therapies for sufferers with RAS-addicted cancers, introduced late Tuesday that it has priced round 14.13 million shares of its frequent inventory at a public providing worth of $46.00 per share.
The corporate can also be providing pre-funded warrants to buy round 2.17 million shares of frequent inventory at a public providing worth of $45.9999, which represents the per share public providing worth for the frequent inventory much less the $0.0001 per share train worth for every pre-funded warrant.
All the shares and pre-funded warrants within the providing are to be offered by Revolution Medicines.
As well as, the corporate has granted the underwriters a 30-day choice to buy as much as a further 2.45 million shares of frequent inventory on the public providing worth, much less underwriting reductions and commissions.
The gross proceeds from the providing could be round $750 million, earlier than deducting underwriting reductions and commissions and different providing bills.
The providing is anticipated to shut on December 5, topic to customary closing situations.
J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are appearing as joint book-running managers for the providing.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
